Patents by Inventor Zurit Levine

Zurit Levine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240082397
    Abstract: The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof. The present invention is directed to monotherapy and combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.
    Type: Application
    Filed: January 28, 2022
    Publication date: March 14, 2024
    Inventors: Mark WHITE, Inbal BARBIRO, Ilan VAKNIN, Assaf WOOL, Zurit LEVINE, Henry Adeboye ADEWOYE, MD, Michael BUCKLEY, Jun LU, John HUNTER, Anat COHEN-DAYAG, Gad S. COJOCARU, Eran OPHIR, Zoya ALTEBER
  • Publication number: 20240076373
    Abstract: The present invention is directed to anti-PVRIG antibodies and stable liquid pharmaceutical formulations thereof. The present invention is directed to monotherapy and combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof. The present invention also provides biomarkers for use in determining populations for treatment with anti-PVRIG antibodies and such biomarkers include, for example PVRIG and/or PVRL2 expression.
    Type: Application
    Filed: January 28, 2022
    Publication date: March 7, 2024
    Inventors: Inbal BARBIRO, Ilan VAKNIN, Assaf WOOL, Zurit LEVINE, Paul A. BASCIANO, Brian D. LAMON, Henry Adeboye ADEWOYE, John HUNTER, Anat COHEN-DAYAG, Gad S. COJOCARU, Eran OPHIR, Zoya ALTEBER
  • Publication number: 20220315641
    Abstract: This invention relates to C10RF32 protein and its variants and fragments and fusion proteins thereof, pharmaceutical composition comprising same and methods of use therof for treatment of immune related disorders and infections.
    Type: Application
    Filed: November 18, 2020
    Publication date: October 6, 2022
    Inventors: Amir TOPORIK, Avi Yeshah ROSENBERG, Galit ROTMAN, Zurit LEVINE, Iris HECHT
  • Publication number: 20210253667
    Abstract: This invention relates to C10RF32 protein and its variants and fragments and fusion proteins thereof, pharmaceutical composition comprising same and methods of use therof for treatment of immune related disorders and infections.
    Type: Application
    Filed: November 18, 2020
    Publication date: August 19, 2021
    Inventors: Amir TOPORIK, Avi Yeshah ROSENBERG, Galit ROTMAN, Zurit LEVINE, Iris HECHT
  • Publication number: 20200002416
    Abstract: This invention relates to C1ORF32-specific antibodies, antibody fragments, alternative scaffolds, conjugates and compositions comprising same, for treatment of cancer.
    Type: Application
    Filed: May 14, 2019
    Publication date: January 2, 2020
    Inventors: Gady S. COJOCARU, Galit ROTMAN, Zurit LEVINE, Liat DASSA, Ofer LEVI, Raffaella BRIANTE, Shweta SINGH, Susan R. WATSON, Tania PERGAM
  • Publication number: 20190248866
    Abstract: This invention relates to C1ORF32 protein and its variants and fragments and fusion proteins thereof, pharmaceutical composition comprising same and methods of use therof for treatment of immune related disorders and infections.
    Type: Application
    Filed: April 30, 2018
    Publication date: August 15, 2019
    Inventors: Amir TOPORIK, Avi Yeshah ROSENBERG, Galit ROTMAN, Zurit LEVINE, Iris HECHT
  • Publication number: 20190231848
    Abstract: This invention relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders.
    Type: Application
    Filed: October 15, 2018
    Publication date: August 1, 2019
    Inventors: Galit ROTMAN, Iris HECHT, Zurit LEVINE, Joseph R. PODOJIL, Stephen D. Miller
  • Publication number: 20180298109
    Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.
    Type: Application
    Filed: January 29, 2018
    Publication date: October 18, 2018
    Inventors: Anat COHEN-DAYAG, Merav BEIMAN, Liat DASSA, Marina BUBIS, Shirley SAMEACH GREENWALD, Dalit LANDESMAN-MILO, Cynthia KOIFMAN, Ofer LEVY, Sergey NEMZER, Tania PERGAM, Yaron KINAR, Zurit LEVINE, Avi ROSENBERG, Galit ROTMAN, Eve MONTIA, Amit NOVIK, Amir TOPORIK, Shira WALACH
  • Patent number: 10098934
    Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: October 16, 2018
    Assignee: COMPUGEN LTD
    Inventors: Zurit Levine, Amir Toporik, Amit Novik, Anat Cohen-Dayag, Avi Rosenberg, Cynthia Koifman, Dalit Landesman-Milo, Eve Montia, Galit Rotman, Liat Dassa, Marina Bubis, Merav Beiman, Ofer Levy, Sergey Nemzer, Shira Walach, Shirley Sameach- Greenwald, Tania Pergam, Yaron Kinar
  • Publication number: 20170232062
    Abstract: This invention relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders.
    Type: Application
    Filed: April 30, 2016
    Publication date: August 17, 2017
    Applicant: Compugen Ltd.
    Inventors: Galit ROTMAN, Iris HECHT, Zurit LEVINE, Joseph R. PODOJIL, Stephen D. MILLER
  • Publication number: 20170233473
    Abstract: This invention relates to C1ORF32-specific antibodies, antibody fragments, alternative scaffolds, conjugates and compositions comprising same, for treatment of cancer.
    Type: Application
    Filed: February 28, 2017
    Publication date: August 17, 2017
    Applicant: Compugen Ltd.
    Inventors: Gady S. COJOCARU, Galit ROTMAN, Zurit LEVINE, Liat DASSA, Ofer LEVI, Raffaella BRIANTE, Shweta SINGH, Susan R. WATSON, Tania PERGAM
  • Publication number: 20170107284
    Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KRTCAP3, FAM26F, MGC52498, FAM70A or TMEM154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages. This invention further relates to extracellular domains of KRTCAP3, FAM26F, MGC52498, FAM70A and TMEM154 proteins and variants, and therapeutic usages thereof.
    Type: Application
    Filed: November 29, 2016
    Publication date: April 20, 2017
    Inventors: Amir TOPORIK, Amit NOVIK, Anat COHEN-DAYAG, Avi Yeshah ROSENBERG, Eve MONTIA, Galit ROTMAN, Liat DASSA, Merav BEIMAN, Ofer LEVY, Shira WALACH, Shirley SAMEACH- GREENWALD, Yaron KINAR, Zurit LEVINE, Gad S. COJOCARU, Sergey NEMZER
  • Patent number: 9617336
    Abstract: This invention relates to C1ORF32-specific antibodies, antibody fragments, alternative scaffolds, conjugates and compositions comprising same, for treatment of cancer.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: April 11, 2017
    Assignee: COMPUGEN LTD
    Inventors: Gady S. Cojocaru, Galit Rotman, Zurit Levine, Liat Dassa, Ofer Levi, Raffaella Briante, Shweta Singh, Susan R. Watson, Tania Pergam
  • Publication number: 20170037141
    Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.
    Type: Application
    Filed: January 30, 2016
    Publication date: February 9, 2017
    Inventors: Anat COHEN-DAYAG, Merav BEIMAN, Liat DASSA, Marina BUBIS, Shirley SAMEACH- GREENWALD, Dalit LANDESMAN-MILO, Cynthia KOIFMAN, Ofer LEVY, Sergey NEMZER, Tania PERGAM, Yaron KINAR, Zurit LEVINE, Avi ROSENBERG, Galit ROTMAN, Eve MONTIA, Amit NOVIK, Amir TOPORIK, Shira WALACH
  • Patent number: 9555087
    Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: January 31, 2017
    Assignee: COMPUGEN LTD
    Inventors: Amir Toporik, Amit Novik, Anat Cohen-Dayag, Avi Yeshah Rosenberg, Cynthia Koifman, Dalit Landesman-Milo, Eve Montia, Galit Rotman, Liat Dassa, Marina Bubis, Merav Beiman, Ofer Levi, Sergey Nemzer, Tania Pergam, Yaron Kinar, Shirley Sameach- Greenwald, Zurit Levine, Shira Walach
  • Publication number: 20160347814
    Abstract: This invention relates to VSTM5 proteins, soluble molecules and fusions thereof which are suitable targets for drug development and for treatment of immune related disorders, immunotherapy, treatment of cancer, infectious disorders and/or sepsis.
    Type: Application
    Filed: March 10, 2016
    Publication date: December 1, 2016
    Inventors: Zurit LEVINE, Galit ROTMAN, Liat DASSA, Ofer LEVY, Gad S. COJOCARU, Amir TOPORIK, Yossef KLIGER, Ilan VAKNIN, Iris HECHT
  • Publication number: 20160304579
    Abstract: This invention relates to C1ORF32 protein and its variants and fragments and fusion proteins thereof, pharmaceutical composition comprising same and methods of use thereof for treatment of immune related disorders and infections.
    Type: Application
    Filed: February 29, 2016
    Publication date: October 20, 2016
    Inventors: Amir TOPORIK, Avi Yeshah ROSENBERG, Galit ROTMAN, Iris HECHT, Zurit LEVINE
  • Publication number: 20160272707
    Abstract: The present invention relates to VSTM5-specific antibodies, antibody fragments, and VSTM5 polypeptides, conjugates and compositions comprising same, for modulating (antagonizing or agonizing) one or more of the effects of VSTM5 expression on immunity. More specifically, the present invention relates to VSTM5-specific antibodies, antibody fragments, and VSTM5 polypeptides, conjugates and compositions comprising same for treating and aiding in the diagnosis of cancer, infectious diseases and immune related diseases, e.g., those associated with aberrant (higher or lower than normal) VSTM5 expression by diseased and/or immune cells and/or aberrant (increased or reduced) VSTM5-mediated effects on immunity.
    Type: Application
    Filed: September 11, 2014
    Publication date: September 22, 2016
    Inventors: Zurit LEVINE, Galit ROTMAN, Liat DASSA, Ofer LEVY, Gad S. COJOCARU, Amir TOPORIK, Yossef KLIGER, Andrew POW, Spencer LIANG
  • Patent number: 9428574
    Abstract: This invention relates to C1ORF32 protein and its variants and fragments and fusion proteins thereof, pharmaceutical composition comprising same and methods of use thereof for treatment of immune related disorders and infections.
    Type: Grant
    Filed: July 1, 2012
    Date of Patent: August 30, 2016
    Assignee: COMPUGEN LTD.
    Inventors: Amir Toporik, Avi Yeshah Rosenberg, Galit Rotman, Iris Hecht, Zurit Levine
  • Patent number: 9428586
    Abstract: The present invention, in at least some aspects, is of splice variants of heparanase, as well as diagnostic kits and methods of use, and therapeutic agents and methods of use based thereon, and antibodies specifically binding thereof.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: August 30, 2016
    Assignee: COMPUGEN LTD
    Inventors: Ronen Shemesh, Michal Ayalon-Soffer, Zurit Levine, Sergey Nemzer, Tomer Zekharya, Gad S. Cojocaru, Uri Barash, Neta Ilan, Israel Vlodavsky, Iris Hecht